Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus

被引:12
作者
Higuchi, Akira [1 ]
Toriniwa, Hiroko [2 ]
Komiya, Tomoyoshi [2 ]
Nakayama, Tetsuo [3 ]
机构
[1] Kitasato Daiichi Sankyo Vaccine, Div Vaccine Prod, Kitamoto City, Saitama 3640026, Japan
[2] Kitasato Daiichi Sankyo Vaccine, Div Vaccine Dev, Kitamoto City, Saitama 3640026, Japan
[3] Kitasato Inst Life Sci, Lab Viral Infect, Tokyo 1088641, Japan
来源
PLOS ONE | 2016年 / 11卷 / 03期
关键词
RANDOMIZED CONTROLLED-TRIAL; NEUTRALIZING ANTIBODY; EDMONSTON-ZAGREB; PHASE-III; FOLLOW-UP; MICE; IMMUNOGENICITY; PROTECTION; INFECTION; RESPONSES;
D O I
10.1371/journal.pone.0150213
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
An inactivated Japanese encephalitis virus (JEV) vaccine, which induces neutralizing antibodies, has been used for many years in Japan. In the present study, the JEV prM-E protein gene was cloned, inserted at the P/M junction of measles AIK-C cDNA, and an infectious virus was recovered. The JEV E protein was expressed in B95a cells infected with the recombinant virus. Cotton rats were inoculated with recombinant virus. Measles PA antibodies were detected three weeks after immunization. Neutralizing antibodies against JEV developed one week after inoculation, and EIA antibodies were detected three weeks after immunization. The measles AIK-C-based recombinant virus simultaneously induced measles and JEV immune responses, and may be a candidate for infant vaccines. Therefore, the present strategy of recombinant viruses based on a measles vaccine vector would be applicable to the platform for vaccine development.
引用
收藏
页数:9
相关论文
共 34 条
  • [21] Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes
    Nam, JH
    Wyatt, LS
    Chae, SL
    Cho, HW
    Park, YK
    Moss, B
    [J]. VACCINE, 1999, 17 (03) : 261 - 268
  • [22] MOLECULAR-BASIS OF ATTENUATION OF NEUROVIRULENCE OF WILD-TYPE JAPANESE ENCEPHALITIS-VIRUS STRAIN SA14
    NI, HL
    CHANG, GJJ
    XIE, H
    TRENT, DW
    BARRETT, ADT
    [J]. JOURNAL OF GENERAL VIROLOGY, 1995, 76 : 409 - 413
  • [23] Nkrumah FK, 1998, B WORLD HEALTH ORGAN, V76, P353
  • [24] Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine:: Requirement for antibody but not CD8+ cytotoxic T-cell responses
    Pan, CH
    Chen, HW
    Huang, HW
    Tao, MH
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (23) : 11457 - 11463
  • [25] Sasaki K, 1974, Kitasato Arch Exp Med, V47, P1
  • [26] AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats
    Sawada, Akihito
    Komase, Katsuhiro
    Nakayama, Tetsuo
    [J]. VACCINE, 2011, 29 (07) : 1481 - 1490
  • [27] A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses
    Sohn, Young Mo
    Tandan, J. B.
    Yoksan, Sutee
    Ji, Min
    Ohrr, Heechoul
    [J]. VACCINE, 2008, 26 (13) : 1638 - 1643
  • [28] Development of Vero cell-derived inactivated Japanese encephalitis vaccine
    Sugawara, K
    Nishiyama, K
    Ishikawa, Y
    Abe, M
    Sonoda, K
    Komatsu, K
    Horikawa, Y
    Takeda, K
    Honda, T
    Kuzuhara, S
    Kino, Y
    Mizokami, H
    Mizuno, K
    Oka, T
    Honda, K
    [J]. BIOLOGICALS, 2002, 30 (04) : 303 - 314
  • [29] Safety and immunogenicity of a Vero-cell-derived,inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
    Tauber, E.
    Kollaritsch, H.
    Korinek, M.
    Rendi-Wagner, P.
    Jilma, B.
    Firbas, C.
    Schranz, S.
    Jong, E.
    Klingler, A.
    Dewasthaly, S.
    Klade, C. S.
    [J]. LANCET, 2007, 370 (9602) : 1847 - 1853
  • [30] TIDJANI O, 1989, LANCET, V2, P1357